Latest Market News

ANZ Bank New Zealand has lodged an appeal against a High Court summary judgment in a class action related to consumer credit laws, prolonging legal uncertainty for the lender.

Bass Oil Limited offers up to 24 million free attaching options to recent placement participants, alongside nearly 8 million options to its lead manager PAC Partners, with no new funds raised from the options issue.

Sarama Resources has secured A$1.42 million through the first tranche of its A$1.5 million equity placement, with the second tranche involving director participation pending shareholder approval.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.

Burger Fuel Group reported a 91.8% surge in net profit to NZD 1.97 million for FY26, driven by sales growth, reduced legal costs, and a one-off store sale gain, despite geopolitical headwinds in the Middle East.

Acrux has locked in a milestone-based licensing agreement worth up to AUD 5.4 million for Lenzetto®, targeting the Australian menopause therapy market with regulatory and commercial milestones tied to TGA approval and sales performance.

Green Technology Metals (ASX: GT1) secured $1.87 million from its recent entitlement offer, with underwriters stepping in to cover a $2.13 million shortfall. The capital raise supports ongoing development of its Ontario lithium project.

New Talisman Gold Mines boosted revenue by 121% to NZ$53,000 but posted a $2.26 million net loss as it commissioned a processing plant and secured key commercial agreements.

Elanor Investors Group has called off its planned acquisition of Singapore-based Firmus Capital due to prolonged regulatory delays, while reaffirming its $125 million recapitalisation with Rockworth Capital Partners and seeking ASX trading reinstatement.

PolyNovo has completed its pivotal US clinical trial report for NovoSorb BTM and adjusted its FDA Premarket Approval submission timeline to late 2026 to incorporate updated regulatory requirements and additional data.

ArborGen Holdings delivered its strongest revenue in five years with $68.2 million, driven by a 14% surge in Brazil and an 8% rise in adjusted EBITDA despite US market headwinds. The company’s focus on advanced genetics and operational efficiency underpins a confident FY27 outlook.

Booster Innovation Fund has trimmed its net asset value per unit to $1.47 following a $723,000 valuation adjustment driven by slower growth and capital raising dynamics in its portfolio.